Drugs / Dermatophagoides pteronyssinus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01115595 | Mar 2010 → Oct 2013 | perennial allergic rhinitis | Pongsakorn Tantilipikorn | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT05450289 Background | Aug 2022 → Mar 2023 | house allergic alveolitis | Universitas Airlangga | Unknown | No outcome recorded |
| — | NCT01291381 Comparator | Feb 2009 → Feb 2010 | allergic rhinitis | Beijing Tongren Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dermatophagoides pteronyssinus | “extract of Dermatophagoides pteronyssinus via subcutaneous injection.” NCT05450289 ↗ |
| Known as | Alutard SQ | “Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol” NCT01291381 ↗ |
| Route | Other | “injection by Mite extract” NCT01115595 ↗ |